|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Zymeworks_Inc.
gptkb:Zymeworks_Biopharmaceuticals
|
|
gptkbp:awards
|
Best Workplace 2021
Top Employer 2020
|
|
gptkbp:ceo
|
gptkb:Ali_Tehrani
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
ZW25 in combination therapy
ZW49 in clinical studies
|
|
gptkbp:collaboration
|
gptkb:Eli_Lilly
gptkb:GSK
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Pfizer
gptkb:Roche
gptkb:Novartis
|
|
gptkbp:collaborations
|
gptkb:Mc_Gill_University
gptkb:Harvard_University
gptkb:University_of_British_Columbia
gptkb:University_of_Toronto
gptkb:Simon_Fraser_University
|
|
gptkbp:focus
|
therapeutics
|
|
gptkbp:founded
|
gptkb:2003
|
|
gptkbp:founder
|
gptkb:Andrew_Hall
gptkb:David_H._H._Lee
gptkb:Michael_R._Mc_Carthy
gptkb:Robert_A._Mc_Carthy
gptkb:Ali_Tehrani
|
|
gptkbp:headcount
|
200+
|
|
gptkbp:headquarters
|
gptkb:Vancouver,_Canada
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zymeworks US, Inc.
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:invention
|
over 100 patents
|
|
gptkbp:investment
|
$100 million
|
|
gptkbp:location
|
gptkb:Canada
gptkb:United_States
|
|
gptkbp:market_cap
|
$1 billion
|
|
gptkbp:number_of_employees
|
over 200
|
|
gptkbp:partnership
|
gptkb:Bristol-Myers_Squibb
gptkb:Merck_&_Co.
|
|
gptkbp:product
|
gptkb:Zymeworks'_ZW25
gptkb:Zymeworks'_ZW49
|
|
gptkbp:research_focus
|
gptkb:Oncology
oncology
rare diseases
autoimmune diseases
chronic diseases
infectious diseases
immunology
|
|
gptkbp:stock_symbol
|
ZYME
|
|
gptkbp:subsidiary
|
gptkb:Zymeworks_Canada,_Inc.
|
|
gptkbp:technology
|
protein engineering
antibody-drug conjugates
bispecific antibodies
|
|
gptkbp:traded_on
|
gptkb:NYSE
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.zymeworks.com
|
|
gptkbp:bfsParent
|
gptkb:Zymeworks_Inc.
|
|
gptkbp:bfsLayer
|
6
|